Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.33 |
| ▸ | TPSAB1 | Q15661 | 7/20 | 0.33 |
| ▸ | TPSD1 | Q9BZJ3 | 7/20 | 0.33 |
| ▸ | TPSG1 | Q9NRR2 | 7/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 5/20 | 0.33 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | TGM2 | P21980 | 2/20 | 0.32 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20032015 | 0.92 | SIGMAR1 (0.32) | SIGMAR1GNAI3GNAI1TPSAB1TPSD1 | |
| SCHEMBL22388961 | 0.88 | NR2F2 (0.33) | SIGMAR1GNAI3GNAI1TPSAB1TPSD1 | |
| SCHEMBL22001231 | 0.87 | GNAI3 (0.33) | SIGMAR1GNAI3GNAI1TPSAB1TPSD1 | |
| SCHEMBL409237 | 0.79 | ITGB3 (0.38) | SIGMAR1GNAI3GNAI1RAB9A | |
| SCHEMBL15443875 | 0.78 | GNAI3 (0.39) | GNAI3GNAI1TPSAB1TPSD1TPSG1 | |
| SCHEMBL20019652 | 0.78 | GNAI3 (0.37) | GNAI3GNAI1TPSAB1TPSD1TPSG1 | |
| SCHEMBL22620788 | 0.77 | GNAI3 (0.40) | GNAI3GNAI1TPSAB1TPSD1TPSG1 | |
| SCHEMBL20032529 | 0.76 | GNAI3 (0.40) | GNAI3GNAI1TPSAB1TPSD1TPSG1 | |
| SCHEMBL15355591 | 0.76 | GNAI3 (0.41) | SIGMAR1GNAI3GNAI1TPSAB1TPSD1 | |
| SCHEMBL14980274 | 0.74 | GNAI3 (0.44) | GNAI3GNAI1TPSAB1TPSD1TPSG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11732259-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11732259-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20210139896-A1 | Peptide Oligonucleotide Conjugates | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2021-05-13 | — | — | US | disclosed |
| US-20210139897-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | SAREPTA THERAPEUTICS, INC. | 2021-05-13 | — | — | US | disclosed |
| US-10760078-B2 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | SAREPTA THERAPEUTICS, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10398721-B2 | Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20190218551-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2019-07-18 | — | — | US | disclosed |
| US-20180092938-A1 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-04-05 | — | — | US | disclosed |
| US-9862946-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2018-01-09 | — | — | US | disclosed |
| US-9833468-B2 | Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9326992-B2 | Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-20160102307-A1 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2016-04-14 | — | — | US | disclosed |
| US-9161948-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-9066967-B2 | Oligonucleotide analogues targeting human LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20150073140-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | SAREPTA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | US | disclosed |
| US-8779128-B2 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | SAREPTA THERAPEUTICS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140024698-A1 | METHODS FOR TREATING PROGEROID LAMINOPATHIES USING OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-20140024821-A1 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-20120289457-A1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | AVI BIOPHARMA, INC. (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120065169-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218551-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | NSUN2, UPF1, RTCB | SIGMAR1 3633/4885GNAI3 2137/4885GNAI1 2326/4885 |
| US-20120065169-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | NSUN2, UPF1, RTCB | SIGMAR1 3633/4885GNAI3 2137/4885GNAI1 2326/4885 |
| US-10398721-B2 | Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA | LMNA, LMNB2, LMNB1 | SIGMAR1 4307/4885GNAI3 1448/4885GNAI1 1599/4885 |
| US-20160102307-A1 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | LMNB2, LMNA, LMNB1 | SIGMAR1 3742/4885GNAI3 1384/4885GNAI1 1430/4885 |
| US-10760078-B2 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | NSUN2, UPF1, RTCB | SIGMAR1 3633/4885GNAI3 2137/4885GNAI1 2326/4885 |
| US-20210139896-A1 | Peptide Oligonucleotide Conjugates | SNRPE, SMN1; SMN2, UPF1 | SIGMAR1 3384/4885GNAI3 3410/4885GNAI1 3224/4885 |
| US-20150073140-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | NSUN2, UPF1, RTCB | SIGMAR1 3633/4885GNAI3 2137/4885GNAI1 2326/4885 |
| US-20140024698-A1 | METHODS FOR TREATING PROGEROID LAMINOPATHIES USING OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | LMNA, LMNB2, LMNB1 | SIGMAR1 4307/4885GNAI3 1448/4885GNAI1 1599/4885 |
| US-20210139897-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | NSUN2, UPF1, RTCB | SIGMAR1 3633/4885GNAI3 2137/4885GNAI1 2326/4885 |
| US-20120289457-A1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | SNRPE, SMN1; SMN2, UPF1 | SIGMAR1 3384/4885GNAI3 3410/4885GNAI1 3224/4885 |
| US-11732259-B2 | Peptide oligonucleotide conjugates | SNRPE, SMN1; SMN2, UPF1 | SIGMAR1 3384/4885GNAI3 3410/4885GNAI1 3224/4885 |
| US-20180092938-A1 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | LMNB2, LMNA, LMNB1 | SIGMAR1 3742/4885GNAI3 1384/4885GNAI1 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.